Novartis AG Stock Price and Value Analysis

Should you buy Novartis AG stock? (NYSE:NVS). Let's see how it does in our automated value investing analysis system.

  • This company has a large dividend yield!
  • This company has stable growth.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.

NVS Free Cash Flow Trend

Hmm, we can't give any reliable projection for Novartis AG's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for NVS
Free Cash Flow trendline for Novartis AG

Inside the NVS Numbers

NVS Price
(Novartis AG stock price per share)
[?] PE Ratio versus Sector 15% higher than other Healthcare stocks
[?] PE Ratio versus Industry 36% higher than other Drug Manufacturers - Major stocks
[?] Cash Yield 4.63%
[?] Free Cash Flow Jitter 19%
[?] Dividend Yield 4%

Is Novartis AG Stock on Sale?

Based on our analysis, we believe that you should not buy Novartis AG right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NVS Stock?

Does Novartis AG have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.